All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for CSL BEHRING LLC · Biotherapeutic company providing recombinant and plasma-derived products.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Pennsylvania · House · Senate · $50,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 5

HR 1476
PLASMA Act
S 694
PLASMA Act
HR 1990
American Innovation and R&D Competitiveness Act of 2025
HR 591
Defending American Jobs and Investment Act
HR 2423
Unfair Tax Prevention Act

Lobbying activity 4

Medicare/Medicaid

Issues related to plasma therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Monitored issues related to pharmacy benefit management.

Health Issues

Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing.

Taxation/Internal Revenue Code

H.R. 1990, the American Innovation and R&D Competitiveness Act, as it relates to the R&D tax credit. Monitored H.R. 591, Defending American Jobs & Investment Act and H.R. 2423, Unfair Tax Prevention Act, as they relate to taxation of foreign-based multinationals. Issues related to the 2025 extension of the Tax Cut and Jobs Act provisions impacting corporations and the Orphan Drug Tax Credit.

Trade (domestic/foreign)

Issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.